Patents by Inventor Jacob Gonzalez Rodriguez

Jacob Gonzalez Rodriguez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors
    Patent number: 10759793
    Abstract: New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: September 1, 2020
    Assignee: Almirall, S.A.
    Inventors: Cristina Esteve Trias, Joan Taltavull Moll, Jacob Gonzalez Rodriguez, Bernat Vidal Juan
  • Imidazo[1,2-]pyridazine and imidazo[4,5-]pyridine derivatives as JAK inhibitors
    Patent number: 9133200
    Abstract: New imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Grant
    Filed: November 24, 2011
    Date of Patent: September 15, 2015
    Assignee: Almirall, S.A.
    Inventors: Jacob Gonzalez Rodriguez, Bernat Vidal Juan, Laura Vidal Gispert, Jordi Bach Taña
  • Substituted spiro[cycloalkyl-1,3?-indo]-2?(1?H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors
    Patent number: 8772288
    Abstract: The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: July 8, 2014
    Assignee: Almirall, S.A.
    Inventors: Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Bernet Vidal Juan, Nuria Aguilar Izquierdo
  • PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES
    Publication number: 20140170110
    Abstract: Compounds having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Application
    Filed: May 21, 2012
    Publication date: June 19, 2014
    Applicant: ALMIRALL, S.A.
    Inventors: Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Elena Gomez Castillo, Jordi Bach Taña
  • IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20130309200
    Abstract: New imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Application
    Filed: November 24, 2011
    Publication date: November 21, 2013
    Applicant: ALMIRALL, S.A.
    Inventors: Jacob Gonzalez Rodriguez, Bernat Vidal Juan, Laura Vidal Gispert, Jordi Bach Taña
  • Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors
    Patent number: 8450341
    Abstract: The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: May 28, 2013
    Assignee: Almirall, S.A.
    Inventors: Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Victor Giulio Matassa
  • HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20130089512
    Abstract: New heteroaryl imidazolone derivatives having the chemical structure of formula (I) are disclosed, as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Application
    Filed: June 14, 2011
    Publication date: April 11, 2013
    Inventors: Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Elena Gomez Castillo, Jordi Bach Taña
  • 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives
    Patent number: 8258122
    Abstract: New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed herein, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: September 4, 2012
    Assignee: Almirall, S.A.
    Inventors: Bernat Vidal Juan, Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Cristina Esteve Trias
  • SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS
    Publication number: 20110053936
    Abstract: The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: April 3, 2009
    Publication date: March 3, 2011
    Inventors: Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Bernat Vidal Juan, Nuria Aguilar Izquierdo
  • SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS
    Publication number: 20110046097
    Abstract: The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: April 16, 2009
    Publication date: February 24, 2011
    Inventors: Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Victor Giulio Matassa
  • Imidazopyridine derivatives as Aadenosine receptor antagonists
    Patent number: 7855202
    Abstract: The present disclosure relates to imidazopyridine derivatives of formula (I): The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A2B adenosine receptor.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: December 21, 2010
    Assignee: Laboratorios Almirall, S.A.
    Inventors: Bernat Vidal Juan, Silvia Fonquerna Pou, Paul Robert Eastwood, Jose Aiguade Bosch, Aranzazu Cardus Figueras, Ines Carranco Moruno, Jacob Gonzalez Rodriguez, Sergio Paredes Aparicio
  • 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES
    Publication number: 20100120731
    Abstract: New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed herein, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.
    Type: Application
    Filed: February 29, 2008
    Publication date: May 13, 2010
    Inventors: Bernat Vidal Juan, Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Cristina Esteve Trias
  • Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists
    Publication number: 20090023763
    Abstract: New antagonists of the A2B adenosine receptor represented by formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of the A2B adenosine receptor.
    Type: Application
    Filed: April 12, 2005
    Publication date: January 22, 2009
    Inventors: Bernat Vidal Juan, Paul Robert Eastwood, Jacob Gonzalez Rodriguez
  • Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists
    Publication number: 20080275038
    Abstract: The present disclosure relates to imidazopyridine derivatives of formula (I): The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A2B adenosine receptor.
    Type: Application
    Filed: October 5, 2006
    Publication date: November 6, 2008
    Inventors: Bernat Vidal Juan, Silvia Fonquerna Pou, Paul Robert Eastwood, Jose Aiguade Bosch, Aranzazu Cardus Figueras, Ines Carranco Moruno, Jacob Gonzalez Rodriguez, Sergio Paredes Aparicio